Literature DB >> 16847299

Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.

Karen C Patterson, Ariel Weissmann, Tahamtan Ahmadi, Harrison W Farber.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847299     DOI: 10.7326/0003-4819-145-2-200607180-00020

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  46 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

Review 3.  Update on pulmonary hypertension 2009.

Authors:  Mark T Gladwin; Hossein-Ardeschir Ghofrani
Journal:  Am J Respir Crit Care Med       Date:  2010-05-15       Impact factor: 21.405

Review 4.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 5.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

6.  Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells.

Authors:  Wenying Ren; Stephanie W Watts; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-24       Impact factor: 5.464

7.  Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.

Authors:  Henrik ten Freyhaus; Daniel Dumitrescu; Henning Bovenschulte; Erland Erdmann; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2009-02-13       Impact factor: 5.460

Review 8.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 9.  Reversible or irreversible remodeling in pulmonary arterial hypertension.

Authors:  Seiichiro Sakao; Koichiro Tatsumi; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-11       Impact factor: 6.914

10.  Treating pulmonary arterial hypertension: current treatments and future prospects.

Authors:  Shahzad G Raja; Shahbaz M Raja
Journal:  Ther Adv Chronic Dis       Date:  2011-11       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.